Amadeus Capital Partners has bought a stake in the Amgen and Illumina-backed company through a secondary transaction, valuing it at around $2.4bn.

Venture capital firm Amadeus Capital Partners has paid $24m to acquire shares in Oxford Nanopore, a UK-based DNA sequencing technology developer backed by corporates Amgen and Illumina, in a secondary transaction. The deal valued Oxford Nanopore at roughly $2.4bn, according to the Telegraph, which said Amadeus had bought into the spinout this way after missing…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.